Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (CDXC) delivers science-backed innovations in healthy aging through its NAD+ research and nutraceutical products. This news hub provides investors and industry stakeholders with essential updates on the company's scientific advancements, regulatory milestones, and market developments.
Access timely press releases covering clinical trial results, patent approvals, and strategic partnerships with research institutions. Track updates across ChromaDex's three core segments: consumer supplements, ingredient licensing, and analytical services supporting product quality assurance.
Our curated news collection enables efficient monitoring of CDXC's progress in translating biochemical research into commercial applications. Bookmark this page for direct access to earnings announcements, product launch details, and peer-reviewed study publications – all critical for evaluating the company's position in the bioscience sector.
ChromaDex Corp. (NASDAQ:CDXC) has partnered with Juvenis to launch its Tru Niagen® supplement in South Korea. Tru Niagen®, a leading Vitamin B3 product, aims to boost NAD+ levels and is recognized for its health benefits. With South Korea projected to see a 23% increase in its elderly population by 2050, the partnership seeks to meet growing demands for health supplements. The product will be available on major platforms including NaverSmartStore and Gmarket. ChromaDex continues to lead research in NAD+ supplementation.
ChromaDex Corp. (NASDAQ:CDXC) will present virtually at the 12th Annual Invitational on June 8, at 4:30 p.m. ET. The event will feature over 200 companies, and ChromaDex's CEO Rob Fried and CFO Kevin Farr will lead the presentation. Additionally, the management team will hold one-on-one meetings with institutional investors throughout the day. Interested parties can find more information and the webcast link on the LD Micro website. ChromaDex is focused on healthy aging and is known for its NAD+ precursor, Niagen®.
ChromaDex Corp. (NASDAQ:CDXC) has announced the establishment of a joint venture, ChromaDex Asia, aimed at distributing its product, Tru Niagen®, in mainland China. The new venture includes partners Crystal Lake Developments, Pioneer Idea Holdings, and Hong Kong Taikuk. Successful commercialization hinges on approval from China's State Administration for Market Regulation, which is critical for health food registration. CEO Rob Fried emphasized this move as a significant milestone in the company’s strategy for the Chinese market, with the JV's formation contingent upon customary closing conditions.
ChromaDex Corp. (NASDAQ:CDXC) reported first-quarter 2022 net sales of $17.3 million, marking an 18% increase year-over-year, primarily driven by a 20% rise in Tru Niagen® sales to $14.9 million. The gross margin decreased to 61.0% from 62.9% due to changes in business mix and increased supply chain costs. Operating expenses rose to $18.3 million, resulting in a net loss of $7.7 million or $(0.11) per share. For 2022, the company anticipates 15-20% revenue growth, with ongoing investment in brand awareness and R&D, despite potential COVID-19 headwinds.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on May 12, 2022, at 4:30 p.m. ET to discuss its first-quarter financial results for the period ending March 31, 2022. The company intends to release these results shortly after market close on the same day. Interested participants should dial in 10 minutes early. A live broadcast and replay of the call will be available on the company's website. ChromaDex specializes in bioscience, focusing on NAD+ research and its flagship product, Niagen.
ChromaDex Corp. (NASDAQ: CDXC) has appointed two new Board members: Kristin Patrick, Chief Marketing Officer of Claire's Inc., and Ann Cohen, CFO of The Institute of Internal Auditors. Patrick has extensive experience in brand strategy from companies like PepsiCo and Playboy, while Cohen brings significant financial expertise from Taylor Morrison Homes and Starwood Vacation Ownership. The company expresses gratitude to departing Board members Jeff Baxter and Caroline Levy, and notes that Kurt Gustafson and Steve Block will not seek re-election at the upcoming annual meeting in June 2022.
ChromaDex (NASDAQ:CDXC) has launched Tru Niagen® Immune, a unique immune health supplement designed to enhance NAD+ levels, vital for aging cells. This product contains a proprietary blend of NAD-boosting Niagen®, vitamins C, D, zinc, and Theracurmin®. NAD+ levels can deplete by up to 80% under immune stress, making this product essential for immune cell function. Retailing at $37.50 for a 30-count bottle, Tru Niagen Immune is now available in the U.S., meeting the growing demand for comprehensive immune support.
ChromaDex Corp. (NASDAQ:CDXC) has been granted a continuation patent, U.S. Patent No. 11,274,117, enhancing its intellectual property for nicotinamide riboside (NR) and other NAD precursors. This patent supports the manufacturing process of NR chloride and new salt forms, crucial for future innovations. With this addition, ChromaDex holds over 40 patents related to Niagen®, its leading product in the healthy aging sector. Both patents expire on November 10, 2037, indicating a strong competitive position in the expanding NAD market.
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
